Abstract
Huntington’s disease (HD) is a devastating, autosomal-dominant inheritance disorder with the progressive loss of medium spiny neurons (MSNs) and corticostriatal connections in the brain. Cell replacement therapy has been proposed as a potential therapeutic strategy to treat HD. Among various types of stem cells, human-induced pluripotent stem cells (iPSCs) have received special attention to develop disease modeling and cell therapy for HD. In the present study, the therapeutic effects of neural precursor cells (NPCs) derived from a human iPSC line (1231A3-NPCs) were investigated in the quinolinic acid (QA)-lesioned rat model of HD. 1231A3-NPCs were transplanted into the ipsilateral striatum 1 week after QA lesioning, and the transplanted animals showed significant behavioral improvements for up to 12 weeks based on the staircase, rotarod, stepping, apomorphine-induced rotation, and cylinder tests. Transplanted 1231A3-NPCs also partially replaced the lost neurons, enhanced endogenous neurogenesis, reduced inflammatory responses, and reconstituted the damaged neuronal connections. Taken together, these results strongly indicate that NPCs derived from iPSCs can potentially be useful to treat HD in the future.
Highlights
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder caused by the abnormal expansion of cytosine-adenine-guanine (CAG) repeats in exon 1 of the huntingtin gene, which encodes a 350-kDa protein termed Huntingtin (MacDonald, 1993)
The differences in the number of retrieved pellets were greater in the 1231A3-neural precursor cells (NPCs) TP group compared with the fibroblast TP and sham groups from 8 weeks post-TP (p < 0.0001 for the 1231A3NPC TP group compared with the fibroblast TP group, p < 0.04 for the 1231A3-NPC TP group compared with the sham group; Figure 1A)
Group difference of falling latency increased progressively over time (p < 0.03 for the 1231A3-NPC TP group compared with the fibroblast TP group at 6 weeks post-TP, p < 0.01 for the 1231A3-NPC TP group compared with the sham group at 8 weeks post-TP, and p < 0.001 for the 1231A3-NPC TP group compared with the sham group at 12 weeks post-TP; Figure 1B)
Summary
Huntington’s disease (HD) is an autosomal-dominant neurodegenerative disorder caused by the abnormal expansion of cytosine-adenine-guanine (CAG) repeats in exon 1 of the huntingtin gene, which encodes a 350-kDa protein termed Huntingtin (MacDonald, 1993). The disease onset typically occurs in middle-aged people in correlation with the length of the CAG expansion (Duyao et al, 1993; Aziz et al, 2018), and the mutation largely causes degeneration of striatal medium spiny neurons (MSNs), resulting in the atrophy of caudate nucleus and putamen, as well as disturbed functions of the basal ganglia in the patient’s brain. Standardization and ethical issues associated with the use of aborted human fetal tissues caused serious limitations (Bjorklund, 1993; Vazey et al, 2006). To overcome these limitations, induced pluripotent stem cells (iPSCs) have emerged as useful candidate cells to treat HD. Because HD is a genetic disease, correction of the mutated gene will be essential for autologous cell therapy (An et al, 2012; Csobonyeiova et al, 2020)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.